Fundz

Gri Bio reported raising $762,000 in an initial SEC Form D filing, from an offering of $762,000

PRIVATEOct 25, 2024

Amount Raised

$762,000

$762,000 sold, per SEC Form D (first sale Oct 21, 2024)

Round Type

Seed

La JollaBiotechnology

Quick answer

GRI Bio raised $762,000 in a Seed round, dated October 21, 2024. GRI Bio is based in La Jolla, California, United States.

How much did GRI Bio raise?
GRI Bio raised $762,000 in a Seed round on October 21, 2024.
What does GRI Bio do?
GRI Bio is a clinical stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated.
Where is GRI Bio based and how big is it?
GRI Bio is based in La Jolla, California, United States.
Who are the decision-makers at GRI Bio?
Fundz holds 1 contact at GRI Bio, including the Executive Officer, Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as GRI Bio that raised within 45 days of this round, from Fundz verified event records.

  • NeuroSense Therapeutics raised $5M on December 5, 2024.
  • AOA Dx raised $1.8M (Seed) on December 5, 2024.
  • Nuvig Therapeutics raised $161M (Series B) on December 5, 2024.
  • miDiagnostics raised $32M (Series D) on December 4, 2024.
  • Nature's Toolbox raised $15M (Funding Round) on December 4, 2024.
  • Refoxy Pharmaceuticals raised $9.6M (Seed) on December 4, 2024.

Who to call at GRI Bio, and when

A new round usually means GRI Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day GRI Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at GRI Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at GRI Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

GRI Bio

Location

2223 AVENIDA DE LA PLAYA, SUITE 208

La Jolla, California, United States

About

GRI Bio is a clinical stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF), a serious disease with significant unmet need. The Company is also developing a pipeline of novel Type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI has the ability to fuel a growing pipeline.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment GRI Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsMarc H., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for GRI Bio's next move

See what Strategic adds

GRI Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.